Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled, multicenter, Phase II study to assess the efficacy and safety of filgotinib administered for 12 weeks to subjects with active ankylosing spondylitis

Next Previous
X
Search
Trial Profile

A randomized, double-blind, placebo-controlled, multicenter, Phase II study to assess the efficacy and safety of filgotinib administered for 12 weeks to subjects with active ankylosing spondylitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Filgotinib (Primary)
  • Indications Ankylosing spondylitis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms TORTUGA
  • Sponsors Galapagos NV

    • Most Recent Events

    • 09 Nov 2021 Results assessing impact of disease on circulating biomarkers at baseline and evaluate the effect of FIL treatment over 12 weeks, presented at the ACR Convergence 2021
    • 09 Nov 2021 Results evaluating the the impact of Filgotinib on transcriptional biomarkers in adult patients with active ankylosing spondylitis presented at the ACR Convergence 2021
    • 14 Oct 2021 Results of this post-hoc analysis evaluating effects of filgotinib on spinal lesions, focusing on inflammatory and fat lesions, in different anatomical locations of the spine in patients from the TORTUGA trialpublished in the Rheumatology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top